STAT October 28, 2024
Andrew Joseph

The company, Ottimo Pharma, is pursuing one of the hottest approaches in immuno-oncology

LONDON — It hasn’t even been a year since Pfizer closed its $43 billion acquisition of Seagen — one of the biggest biopharma deals in years — but David Epstein, who was CEO of Seagen, is back.

Epstein...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights
Biotech startups are built on venture capital. Track funding rounds here.
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
What might a Trump administration mean for the Biosecure Act?

Share This Article